ABEO Abeona Therapeutics Inc.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Company profile
Ticker
ABEO
Exchange
Website
CEO
Joao Siffert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Access Pharmaceuticals Inc, Chemex Pharmaceuticals Inc, Plasmatech Biopharmaceuticals Inc
SEC CIK
Corporate docs
IRS number
830221517
ABEO stock data
()
Investment data
Securities sold
Number of investors
Calendar
10 Aug 20
11 Aug 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Net income | -13.01M | -48.16M | -16.43M | -17.37M | |
| Diluted EPS | -0.14 | -0.52 | -0.3 | -0.35 | |
| Operating income | -12.48M | -48.21M | -16.41M | -17.65M | |
| Net change in cash | -25.61M | -89.1M | 81.34M | 5.31M | |
| Cash on hand | 14.54M | 40.16M | 129.26M | 47.92M | |
| Cost of revenue |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 3M | 837K | 889K | ||
| Net income | -76.28M | -56.67M | -27.32M | -21.87M | |
| Diluted EPS | -1.51 | -1.19 | -0.66 | -0.64 | |
| Net profit margin | -1890% | -3264% | -2460% | ||
| Operating income | -77.09M | -58.17M | -27.84M | -23.88M | |
| Net change in cash | 110.51M | -119M | 68.61M | 29M | |
| Cash on hand | 129.26M | 18.75M | 137.75M | 69.14M | |
| Cost of revenue |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 17 Jun 20 | Migausky George V | Common Stock | Grant | Aquire A | No | 0 | 37,954 | 0 | 37,954 |
| 17 Jun 20 | Migausky George V | Stock Option Common Stock | Grant | Aquire A | No | 3.03 | 45,566 | 138.06K | 45,566 |
| 17 Jun 20 | Mann Paul Elliot | Common Stock | Grant | Aquire A | No | 0 | 37,954 | 0 | 37,954 |
| 17 Jun 20 | Mann Paul Elliot | Stock Option Common Stock | Grant | Aquire A | No | 3.03 | 45,566 | 138.06K | 45,566 |
| 20 May 20 | Buono Stefano | Common Stock | Grant | Aquire A | No | 0 | 17,969 | 0 | 287,969 |
| 20 May 20 | Buono Stefano | Stock Option Common Stock | Grant | Aquire A | No | 3.2 | 21,518 | 68.86K | 21,518 |
Institutional ownership Q1 2020
53.1% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 87 |
| Opened positions | 12 |
| Closed positions | 21 |
| Increased positions | 31 |
| Reduced positions | 23 |
13F shares |
Current |
|---|---|
| Total value | 127.47M |
| Total shares | 44.48M |
| Total puts | 78.4K |
| Total calls | 77.6K |
| Total put/call ratio | 1.0 |
Largest owners |
Shares | Value |
|---|---|---|
| Great Point Partners | 7.21M | $15.15M |
| Adage Capital Partners GP, L.L.C. | 5.5M | $11.55M |
| Wellington Management | 5.44M | $11.43M |
| BLK BlackRock | 3.67M | $7.7M |
| Vanguard | 2.92M | $6.14M |
| Knoll Capital Management | 2.86M | $6.01M |
| Point72 Asset Management | 1.68M | $3.52M |
| Baker Bros. Advisors | 1.59M | $3.34M |
| Perceptive Advisors | 1.5M | $3.06M |
| Citadel Advisors | 1.37M | $2.87M |
Financial report summary
?Competition
Fibrocell Science • Soligenix • Midatech Pharma US • Voyager • Jazz Pharmaceuticals • Alder Biopharmaceuticals • Synedgen • AVAXIA BIOLOGICS • Galera Therapeutics • uniQureManagement Discussion
- Foundation revenues relate to a collaborative agreement between nine Sanfilippo foundations and us to provide up to approximately $13.9 million of grants to us in installments for the advancement of our clinical stage gene therapies for MPS IIIA and MPS IIIB, subject to the achievement of certain milestones. We have received $5.7 million of such grants cumulatively as of December 31, 2019. The cash received upfront from the foundations is deferred on the consolidated balance sheet until the costs of the activities as outlined in the manufacturing and clinical work plan are incurred by installment as outlined in the agreement with the foundations. As a result, we record foundation revenues to match the costs of the activities by installment performed under the collaborative agreement. Our foundation revenue was $0 for the year ended December 31, 2019, as compared to $2.8 million for the same period of 2018. We did not record foundation revenue in 2019 since we have previously recognized revenue up to the amount of cash received to date by installment performed.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Absent, Additionally, administered, Aid, alternative, American, analyzing, authorized, Brian, Carolina, Carr, certification, certify, Chapel, civil, claim, consume, controversy, counterclaim, coverage, criminal, criteria, deferral, detail, disbursed, document, duly, Edward, embedded, evolve, evolving, exhibit, faith, forgiven, formatted, found, gradually, half, harm, hereof, Hill, inaccurate, Index, ineligible, Inline, Interactive, interpretation, irrespective, language, loan, local, media, mortgage, nil, North, ongoing, owed, Page, panel, Paycheck, payroll, Pereira, portion, PPP, prevail, proposed, qualification, Quarterly, reinstituting, Restated, Rule, satisfied, SBA, scalability, Siffert, Small, temporarily, thereunto, undersigned, unforgiven, VIITALTM, XBRL
Removed:
Chairman, human, installment, recent, scale, Stanford
Financial reports
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
16 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
10 May 19
10-K
2018 FY
Annual report
18 Mar 19
10-Q
2018 Q3
Quarterly report
9 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
Current reports
8-K
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
10 Aug 20
8-K
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors
23 Jun 20
8-K
Departure of Directors or Certain Officers
21 May 20
8-K
Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
6 May 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Apr 20
8-K
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors
21 Apr 20
8-K
Departure of Directors or Certain Officers
6 Apr 20
8-K
Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates
16 Mar 20
8-K
Departure of Directors or Certain Officers
16 Mar 20
8-K
Departure of Directors or Certain Officers
8 Jan 20
Registration and prospectus
S-8
Registration of securities for employees
21 May 20
424B5
Prospectus supplement for primary offering
23 Dec 19
25-NSE
Exchange delisting
20 Dec 19
424B5
Prospectus supplement for primary offering
20 Dec 19
424B5
Prospectus supplement for primary offering
17 Aug 18
S-3/A
Shelf registration (amended)
1 Jun 18
S-3
Shelf registration
11 May 18
RW
Registration withdrawal request
16 Mar 18
S-8
Registration of securities for employees
14 Nov 17
424B5
Prospectus supplement for primary offering
17 Oct 17
Proxies
PX14A6G
Letter to shareholders
29 Apr 20
DEFA14A
Additional proxy soliciting materials
23 Apr 20
DEF 14A
Definitive proxy
10 Apr 20
DEF 14A
Definitive proxy
11 Apr 19
DEF 14A
Definitive proxy
10 Apr 18
DEF 14A
Definitive proxy
11 Apr 17
DEF 14A
Definitive proxy
6 Apr 16
DEF 14A
Definitive proxy
7 Apr 15
DEF 14C
Information statement
2 Oct 14
PRE 14C
Preliminary information
29 Sep 14
Other
UPLOAD
Letter from SEC
24 Sep 19
CORRESP
Correspondence with SEC
20 Sep 19
UPLOAD
Letter from SEC
18 Sep 19
CORRESP
Correspondence with SEC
20 Aug 19
UPLOAD
Letter from SEC
6 Aug 19
CT ORDER
Confidential treatment order
3 Apr 19
EFFECT
Notice of effectiveness
8 Jun 18
EFFECT
Notice of effectiveness
3 May 17
UPLOAD
Letter from SEC
31 Jan 17
CORRESP
Correspondence with SEC
25 Jan 17
Ownership
SC 13G
ABEONA THERAPEUTICS / GREAT POINT PARTNERS ownership change
7 Jul 20
4
ABEONA THERAPEUTICS / GEORGE V MIGAUSKY ownership change
19 Jun 20
4
ABEONA THERAPEUTICS / Paul Elliot Mann ownership change
19 Jun 20
3
ABEONA THERAPEUTICS / GEORGE V MIGAUSKY ownership change
19 Jun 20
3
ABEONA THERAPEUTICS / Paul Elliot Mann ownership change
19 Jun 20
4
ABEONA THERAPEUTICS / Shawn Tomasello ownership change
22 May 20
4
ABEONA THERAPEUTICS / Todd Wider ownership change
22 May 20
4
ABEONA THERAPEUTICS / Christine Berni Silverstein ownership change
22 May 20
4
ABEONA THERAPEUTICS / Steven H Rouhandeh ownership change
22 May 20
4
ABEONA THERAPEUTICS / Joao MD Siffert ownership change
22 May 20